{"entity":{"id":"coherence-neuro","kind":"company","name":"Coherence Neuro","aka":["Coherence","Coherence Neuro Australia Pty Limited"],"tldr":"Coherence Neuro is building implanted devices that read and stimulate electrical activity around brain tumours, with the aim of tracking and eventually treating cancer in real time. Its first study records brain signals during surgery for newly diagnosed glioma.","summary":"Coherence Neuro designs therapeutic neurotechnology for cancer: implantable read and write devices intended to track tumours through electrical biomarkers and treat them with electrical stimulation in a closed loop. Its flagship SOMA-1 is described as a minimally invasive, MRI-safe brain-computer interface implanted during existing neurosurgery to monitor and treat conditions such as gliomas. Its first-in-human study, sponsored by Coherence Neuro Australia Pty Limited, uses the CIPHER System, an electrocorticography probe on the brain surface for neural recording and stimulation, during surgery for newly diagnosed glioma at the Royal Melbourne Hospital (NCT07465796); the company announced in June 2026 that procedures had begun. In 2026 it announced USD 45 million from Founders Fund and The OpenAI Startup Fund, which it calls its Series A, with Lux Capital, 8VC, Timeless, Olive Capital and Ahren joining, and named a first chronic human trial in glioblastoma as a goal. Its first registered cancer trial, NCT07465796, was posted on ClinicalTrials.gov in March 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.coherenceneuro.com/"},{"label":"Funding article: Inventing cancer therapy that learns","url":"https://www.coherenceneuro.com/article/inventing-cancer-therapy-that-learns"},{"label":"First clinical study started, June 2026","url":"https://www.coherenceneuro.com/article/coherence-neuro-has-started-its-first-clinical-study"},{"label":"ClinicalTrials.gov: first-in-human study of the CIPHER System (NCT07465796)","url":"https://clinicaltrials.gov/study/NCT07465796"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":["devices"],"technologies":["nerve-tumour-denervation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The technology link is to OnCo's cancer neuroscience record, the nearest fit for an implanted device that records and stimulates brain activity around a glioma; the device does not cut nerves.","Founding year not stated on the website. Offices named in the funding article are San Francisco and Cambridge (UK); San Francisco is used as headquarters, and the registry sponsor is the Australian subsidiary.","The company's claims of an electrical biomarker of cancer rest on preclinical mouse work; no human results were read.","Company website and articles read on 29 October 2026."],"hq":"San Francisco, CA","country":"US","companyType":"devices","website":"https://www.coherenceneuro.com/","stage":"startup","investors":["founders-fund","lux-capital"],"funding":[{"round":"Series A","year":2026,"amountUsd":45000000,"source":"https://www.coherenceneuro.com/article/inventing-cancer-therapy-that-learns","note":"Co-led by Founders Fund and The OpenAI Startup Fund; the article is headed 2026 and the website's article list calls it the Series A."}]},"route":"/companies/coherence-neuro/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"section":[{"id":"devices","kind":"section","name":"Devices & Physical Therapies","route":"/fronts/devices/"}],"technology":[{"id":"nerve-tumour-denervation","kind":"technology","name":"Cancer neuroscience: cutting the nerve supply","route":"/technologies/nerve-tumour-denervation/"}],"company":[{"id":"founders-fund","kind":"company","name":"Founders Fund","route":"/companies/founders-fund/"},{"id":"lux-capital","kind":"company","name":"Lux Capital","route":"/companies/lux-capital/"}]}}